Home › Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea
 

Keywords :   


Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea

2015-12-07 14:00:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Samsung Bioepis Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis RENFLEXIS in Korea as part of Mercks commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: korea samsung approval receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 4
29.06Tropical Storm Beryl Wind Speed Probabilities Number 4
29.06Tropical Storm Beryl Public Advisory Number 4
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Forecast Advisory Number 4
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
More »